View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 28, 2022

Pfizer, BioNTech begin Phase II trial of ‘enhanced’ Covid-19 vaccine

The trial of BNT162b5 vaccine in the US will enrol nearly 200 subjects aged between 18 and 55 years.

Pfizer and BioNTech have commenced a Phase II clinical trial of an ‘enhanced’ Covid-19 messenger ribonucleic acid (mRNA)-based vaccine candidate, BNT162b5.

The next-generation bivalent vaccine, BNT162b5 comprises RNAs that encode improved prefusion spike proteins for the ancestral strain and Omicron variant of the SARS-CoV-2 virus. 

The randomised, active-controlled, observer-blind trial will analyse the safety, tolerability and immune response of the vaccine at a dose level of 30µg.

The trial in the US, which will not have a placebo, will enrol nearly 200 subjects aged between 18 and 55 years. 

These subjects should have previously received a booster shot of a US-authorised Covid-19 vaccine a minimum of 90 days before the first trial visit. 

Participants will be categorised based on the number of months from the last vaccine dose before entering the trial.

The enhanced spike protein encoded from the mRNAs in the vaccine was updated to boost immune response strength and breadth to offer better protection against Covid-19.

According to a press statement, Pfizer said: “This is the first of multiple vaccine candidates with an enhanced design which the companies plan to evaluate as part of a long-term scientific Covid-19 vaccine strategy to potentially generate more robust, longer-lasting, and broader immune responses against SARS-CoV-2 infections and associated Covid-19.”

Earlier this month, the US Food and Drug Administration approved Pfizer and BioNTech’s supplemental Biologics License Application for their Covid-19 vaccine, Comirnaty, for adolescents aged 12 to 15 years.

Comirnaty is said to be the first Covid-19 shot to receive FDA approval for adolescents.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena